Ozempic 3.0? This drug causes the greatest weight loss — by far
Ozempic 3.0? Retatrutide — an experimental drug nicknamed “triple G” — could be your best shot at a slimmer waistline when it becomes available to the public, a Monday study found. Obese adults who took the weekly injection lost up to 22% of their starting weight after 11 months — compared to just 14% over 15 months for semaglutide,
Some GLP-1s Achieve More Weight Loss Than Others: Study
By comparison, the FDA-approved drug liraglutide only resulted in just under 6% weight loss after 26 weeks, the researchers found. Common adverse side effects from the drugs included nausea, vomiting, diarrhea and constipation, researchers noted. However, side effects so bad people had to stop taking the drugs were rare.
GLP-1 RAs efficacious for weight loss in overweight, obesity without diabetes
For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious for weight loss, according to a review published online Jan. 7 in the Annals of Internal Medicine.
GLP-1s cut surgery complication risk in some patients: Study
Glucagon-like peptide-1 receptor agonist drugs may reduce the risk of surgical complications in diabetic patients, according to a large new study. The study showed diabetic patients taking GLP-1 drugs,
How Effective Are GLP-1 Meds for Weight Loss in People Without Diabetes?
At least 95 people have been killed. How Effective Are GLP-1 Meds for Weight Loss in People Without Diabetes? A pensioner living next to a new major road project will access his home through a 'private' TUNNEL - that could cost up to £6M.
Health Matters: GLP-1 drugs work for weight loss, study finds
McGill University researchers say their study has found GLP-1 drugs are safe and effective for treating obesity and overweight adults without diabetes. The authors say the findings support using the medication to treat those who are overweight and obese among otherwise healthy patients.
Novo Nordisk Pushes FDA To Exclude Compounding For Its Early-Generation Diabetes Drug
Novo Nordisk petitions the FDA to exclude liraglutide from the 503B Bulks List, citing safety risks, lack of clinical need, ...
BioSpace2d
Novo Launches Citizen Petition to Block Compounded Victoza
In its Citizen Petition to the FDA, Novo Nordisk argued that there is no clinical need to allow compounding for liraglutide, ...
pulmonologyadvisor2d
FDA Approves First Generic Version of Victoza for Type 2 Diabetes
The FDA has approved Liraglutide Injection, the first generic version of Victoza, for the treatment of type 2 diabetes.
Becker's Hospital Review14h
Novo Nordisk joins Eli Lilly in legal challenge over GLP-1 compounding
The move intensifies an ongoing legal battle, as Novo Nordisk joins its major competitor Eli Lilly in opposing a recent initiative by the Outsourcing Facilities Association to include liraglutide in ...
FiercePharma5d
Novo asks FDA to restrict Victoza compounding amid GLP-1 outsourcing row
In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...
McKnight's Long-Term Care News8d
FDA approves first generic liraglutide once-daily injection
The US Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma Pharmaceuticals), ...
Novo Nordisk seeks to block compounded Victoza
Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of ...
HealthDay on MSN13d
FDA Approves Generic GLP-1 Medicine For Diabetes Treatment
The U.S. Food and Drug Administration (FDA) announced on Monday the approval of the first generic version of a ...
Psychology Today12d
GLP-1RAs in People With Higher Weight and Eating Disorders
GLP-1 receptor agonist weight loss drugs can negatively interact with eating disorder psychopathology and treatment in ...